

Curriculum Vitae

Nome: Trojano Maria	Titolo: Direttore del Dipartimento di Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Università degli Studi "Aldo Moro" Bari, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italia Telefono: + 39 080 5478555 + 39 080 5478555/ Abitazione: 0805215484 Fax: + 39 080 5478532 E-mail: maria.trojano@uniba.it
---------------------	---

Formazione

Istituzione e località	Titolo	Anno di conferimento	Campo di studio
Università degli Studi di Bari, Bari, Italia	Laurea in Medicina	07/ 1977	Neurochimica
Università degli Studi di Bari, Bari, Italia	Specializzazione in Neurologia	07/1981	Studi di prognosi sulla Sclerosi Multipla
Università degli Studi di Bari, Bari, Italia	Specializzazione in Immunologia e Allergologia	07/1985	Neuroimmunologia

Esperienza professionale

Posizione Universitaria attualmente ricoperta:

Professore Ordinario di Neurologia

Incarichi e responsabilità:

- Dal 2012 Direttore del Dipartimento Universitario di Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Università degli Studi Bari

- Dal 2005 Direttore dell'U.O. Complessa di Neurofisiopatologia Università degli Studi Bari.

Incarichi Internazionali

- dal 2012:
Presidente della European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

- dal 2008 al 2009:

Direttore dell'International Board MSBase (MSBase Foundation, Melbourne, Australia)

- dal 2002 al 2003:

Componente del "Medical and Scientific Board of Multiple Sclerosis International Federation, (MSIF)

- dal 1997 al 2000:

Componente dello Scientist Panel (Delegato per l' Italia per l' area: "Spinal Fluid and Hydrocephalus") dell' European Federation of Neurological Societies (EFNS)

- dal 1994 al 1996:

Membro del "Cerebrospinal Fluid Research Group della Federazione Mondiale di Neurologia

- dal 1991 al 2000:

Componente della " Cerebrospinal Fluid Committee of the European Concerted Action for Multiple Sclerosis" della Charcot Foundation

Principali interessi di ricerca:

Neurochimica, Neuroimmunologia , Neuroepidemiologia e conduzione di Studi clinici nelle malattie demielinizzanti

Produzione Scientifica:

Autrice di 200 pubblicazioni su riviste internazionali con alto Impact Factor e di numerosi capitoli di libri nel campo della Neurologia

Publications

- 1: Capra R, Battaglia MA, Gaudio A, Lopes L, Paolicelli D, Paoloni M, Pozzilli C, Santilli V, Solaro C, Trojano M. The MoSt Project--More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. *J Neurol*. 2014 Jan 22.
- 2: Miller DH, Fazekas F, Montalban X, Reingold SC, Trojano M. Pregnancy, sex and hormonal factors in multiple sclerosis. *Mult Scler*. 2014 Jan 20.
- 3: Giordano A, Lugaresi A, Confalonieri P, Granella F, Radice D, Trojano M, Martinelli V, Solari A; on behalf of the SIMS-Practice group. Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. *Mult Scler*. 2014 Jan 13.
- 4: Portaccio E, Ghezzi A, Hakiki B, Sturchio A, Martinelli V, Moiola L, Patti F, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; for the MS Study Group of the Italian Neurological Society. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. *J Neurol Neurosurg Psychiatry*. 2014 Jan 8.
- 5: Bassi M, Falautano M, Cilia S, Goretti B, Grobberio M, Pattini M, Pietrolongo E, Viterbo RG, Amato MP, Benin M, Lugaresi A, Martinelli V, Montanari E, Patti F, Trojano M, Delle Fave A. The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. *J Neurol Sci*. 2014 Feb 15;337(1-2):67-73.
- 6: Pisani F, Sparaneo A, Tortorella C, Ruggieri M, Trojano M, Mola MG, Nicchia GP, Frigeri A, Svelto M. Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. *PLoS One*. 2013 Nov 15;8(11):e79185.
- 7: Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group. Sex as a determinant of

relapse incidence and progressive course of multiple sclerosis. *Brain*. 2013 Dec;136(Pt 12):3609-17.

8: Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group. Subcutaneous interferon β -1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. *PLoS One*. 2013 Aug 30;8(8):e74111.

9: Tortorella C, Drenzo V, D'Onghia M, Trojano M. Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. *Neurology*. 2013 Oct 15;81(16):1470-1.

10: Hughes SE, Spelman T, Gray OM, Boz C, Trojano M, Lugaresi A, Izquierdo G, Duquette P, Girard M, Grand'maison F, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Giuliani G, Lechner-Scott J, Barnett M, Edite Rio M, Pesch VV, Amato MP, Iuliano G, Slee M, Verheul F, Cristiano E, Fernández-Bolaños R, Poehlau D, Saladino ML, Deri N, Cabrera-Gomez J, Vella N, Herbert J, Skromne E, Savino A, Shaw C, Moore F, Vucic S, Petkowska-Boskova T, McDonnell G, Hawkins SA, Kee F, Butzkueven H. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. *Mult Scler*. 2014 Jan 14.

11: Goretti B, Viterbo RG, Portaccio E, Niccolai C, Hakiki B, Piscolla E, Iaffaldano P, Trojano M, Amato MP. Anxiety state affects information processing speed in patients with multiple sclerosis. *Neurol Sci*. 2013 Sep 27.

12: Comi G, Battaglia MA, Bertolotto A, Del Sette M, Ghezzi A, Malferrari G, Salvetti M, Sormani MP, Tesio L, Stolz E, Zaratin P, Mancardi G; CoSMo Collaborative Study Group. Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. *Mult Scler*. 2013 Oct;19(11):1508-17.

13: Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. *Brain Behav Immun*. 2014 Jan;35:96-101.

14: Amato MP, Goretti B, Viterbo RG, Portaccio E, Niccolai C, Hakiki B, Iaffaldano P, Trojano M. Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. *Mult Scler*. 2014 Jan;20(1):91-8.

15: Filippi M, Rocca MA, Bastianello S, Comi G, Gallo P, Gallucci M, Ghezzi A, Marrosu MG, Minonzio G, Pantano P, Pozzilli C, Tedeschi G, Trojano M, Falini A, De Stefano N. Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. *Neurol Sci.* 2013 Dec;34(12):2085-93.

16: Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, Grammond P, Lugaresi A, Hupperts R, Cristiano E, Van Pesch V, Grand'maison F, La Spitaleri D, Rio ME, Flechter S, Oreja-Guevara C, Giuliani G, Savino A, Amato MP, Petersen T, Fernandez-Bolanos R, Bergamaschi R, Iuliano G, Boz C, Lechner-Scott J, Deri N, Gray O, Verheul F, Fiol M, Barnett M, van Munster E, Santiago V, Moore F, Slee M, Saladino ML, Alroughani R, Shaw C, Kasa K, Petkovska-Boskova T, den Braber-Moerland L, Chapman J, Skromne E, Herbert J, Poehlau D, Needham M, Bacile EA, Arruda WO, Paine M, Singhal B, Vucic S, Cabrera-Gomez JA, Butzkueven H; MSBase Study Group. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. *PLoS One.* 2013 May 21;8(5):e63480.

17: Viterbo RG, Iaffaldano P, Trojano M. Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. *J Neurol Sci.* 2013 Jul 15;330(1-2):56-60.

18: Pietrolongo E, Giordano A, Kleinfeld M, Confalonieri P, Lugaresi A, Tortorella C, Pugliatti M, Radice D, Goss C, Heesen C, Solari A; AutoMS group. Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. *PLoS One.* 2013;8(4):e60721.

19: Galeotti F, Massari M, D'Alessandro R, Beghi E, Chiò A, Logroscino G, Filippini G, Benedetti MD, Pugliatti M, Santuccio C, Raschetti R; ITANG study group. Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. *Eur J Epidemiol.* 2013 May;28(5):433-44.

20: Girolamo F, Lia A, Amati A, Strippoli M, Coppola C, Virgintino D, Roncali L, Toscano A, Serlenga L, Trojano M. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. *Neuropathol Appl Neurobiol.* 2013 Mar 4. doi: 10.1111/nan.12040.

21: Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMPO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. *Mult Scler.* 2013 Sep;19(10):1310-9.

22: Paolicelli D, D'Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavalpe V, Trojano M. The impact of neutralizing antibodies on the risk of disease worsening in interferon β -treated relapsing multiple sclerosis: a 5 year post-marketing study. *J Neurol*. 2013 Jun;260(6):1562-8.

23: Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. *Mult Scler*. 2013 Jul;19(8):1106-12.

24: Trojano M. Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword. *Expert Rev Neurother*. 2013 Feb;13(3 Suppl 1):1.

25: Tortorella C, Romano R, Direnzo V, Taurisano P, Zoccolella S, Iaffaldano P, Fazio L, Viterbo R, Popolizio T, Blasi G, Bertolino A, Trojano M. Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. *Mult Scler*. 2013 Aug;19(9):1153-60.

26: Pugliatti M, Eskic D, Mikolcić T, Pitschnau-Michel D, Myhr KM, Sastre-Garriga J, Otero S, Wiczynska L, Torje C, Holloway E, Rienhoff O, Friede T, Buckow K, Ellenberger D, Hillert J, Glaser A, Flachenecker P, Fuge J, Schyns-Liharska T, Kasilingam E, Moretti A, Thalheim C; EUREMS Consortium. Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. *Acta Neurol Scand Suppl*. 2012;(195):24-30.

27: Pastò L, Portaccio E, Ghezzi A, Hakiki B, Giannini M, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi GL, Solaro C, Totaro R, Tola MR, Di Tommaso V, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. *BMC Neurol*. 2012 Dec 31;12:165.

28: Messmer Uccelli M, Traversa S, Trojano M, Viterbo RG, Ghezzi A, Signori A. Lack of information about multiple sclerosis in children can impact parents' sense of competency and satisfaction within the couple. *J Neurol Sci*. 2013 Jan 15;324(1-2):100-5.

29: Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M,

Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Dorenzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group. Geographical variations in sex ratio trends over time in multiple sclerosis. *PLoS One*. 2012;7(10):e48078.

30: Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. *BMC Neurol*. 2012 Oct 22;12:124.

31: Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, Amato MP, Grand'maison F, Butzkueven H, Marrosu M, Duquette P, Comi G, Izquierdo G, Grammond P, Lus G, Petersen T, Bergamaschi R, Giuliani G, Boz C, Coniglio G, Van Pesch V, Lechner-Scott J, Cavalla P, Granella F, Avolio C, Fiol M, Poehlau D, Saladino ML, Gallo P, Deri N, Oleschko Arruda W, Paine M, Ferro M, Barnett M, Cabrera-Gomez JA, Slee M, Moore F, Shaw C, Petkovska-Boskova T, Rutherford M, Engelsen O, Damoiseaux J, Hupperts R. Fluctuations of MS births and UV-light exposure. *Acta Neurol Scand*. 2013 May;127(5):301-8.

32: Zoccolella S, Tortorella C, Iaffaldano P, Dorenzo V, D'Onghia M, Luciannatelli E, Paolicelli D, Livrea P, Trojano M. Low serum urate levels are associated to female gender in multiple sclerosis patients. *PLoS One*. 2012;7(7):e40608.

33: Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, Grand'Maison F, Oreja-Guevara C, Boz C, Lugaresi A, Girard M, Grammond P, Iuliano G, Fiol M, Cabrera-Gomez JA, Fernandez-Bolanos R, Giuliani G, Lechner-Scott J, Cristiano E, Herbert J, Petkovska-Boskova T, Bergamaschi R, van Pesch V, Moore F, Vella N, Slee M, Santiago V, Barnett M, Havrdova E, Young C, Sirbu CA, Tanner M, Rutherford M, Butzkueven H; MSBasis Study Group. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. *PLoS One*. 2012;7(6):e38661.

34: Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V, Romani A, Tortorella C, Portaccio E, D'Onghia M, Garberi F, Bargiggia V, Trojano M. Immunomodulatory therapies delay disease progression in multiple sclerosis. *Mult Scler*. 2012 May 31.

35: Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, Dorenzo V, D'Onghia M, Zoccolella S, Amato MP, Trojano M. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a

prospective, open-label, two years observational study. PLoS One. 2012;7(4):e35843.

36: de Tommaso M, Ceci E, Pica C, Trojano M, Delussi M, Franco G, Livrea P, Ruggieri M. Serum levels of N-acetyl-aspartate in migraine and tension-type headache. *J Headache Pain*. 2012 Jul;13(5):389-94.

37: Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand'Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J; MSBase Investigators. Increasing age at disability milestones among MS patients in the MSBase Registry. *J Neurol Sci*. 2012 Jul 15;318(1-2):94-9.

38: Ciccone MM, Galeandro AI, Scicchitano P, Zito A, Gesualdo M, Sassara M, Cortese F, Dachille A, Carbonara R, Federico F, Livrea P, Trojano M. Multigate quality Doppler profiles and morphological/hemodynamic alterations in multiple sclerosis patients. *Curr Neurovasc Res*. 2012 May;9(2):120-7.

39: Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, Bombelli R, Ferrari M, Ghezzi A, Comi G, Livrea P, Lecchini S, Marino F. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon- β therapy. *Neuroimmunomodulation*. 2012;19(5):283-92.

40: Zoccolella S, Tortorella C, Iaffaldano P, Direnzo V, D'Onghia M, Paolicelli D, Livrea P, Trojano M. Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. *J Neurol*. 2012 Oct;259(10):2105-10.

41: Caragnano M, Tortorella P, Bergami A, Ruggieri M, Livrea P, Specchio LM, Martino G, Trojano M, Furlan R, Avolio C. Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. *J Neuroimmunol*. 2012 Apr;245(1-2):93-7.

42: Hughes S, Spelman T, Trojano M, Lugaresi A, Izquierdo G, Grand'maison F, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Boz C, Bergamaschi R, Giuliani G, Rio ME, Lechner-Scott J, van Pesch V, Iuliano G, Fiol M, Verheul F, Barnett M, Slee M, Herbert J, Kister I, Vella N, Moore F, Petkovska-Boskova T, Shaygannejad V, Jokubaitis V, McDonnell G, Hawkins S, Kee F, Gray O, Butzkueven H; MSBase Study Group. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. *J Neurol Neurosurg Psychiatry*. 2012 Mar;83(3):305-10.

43: Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, Grand'Maison F, Gomez JA, Izquierdo G, Duquette P, Girard M, Grammond P, Oreja-Guevara C, Hupperts R, Bergamaschi R, Boz C, Giuliani G, van Pesch V, Iuliano G, Fiol M, Cristiano E, Verheul F, Saladino ML, Slee M, Barnett M, Deri N, Flechter S, Vella N, Shaw C, Herbert J, Moore F, Petkovska-Boskova T, Jokubaitis V, Butzkueven H; MSBase study group. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. *Mult Scler*. 2012 Jul;18(7):974-82.

44: Iaffaldano P, Lucchese G, Trojano M. Treating multiple sclerosis with natalizumab. *Expert Rev Neurother*. 2011 Dec;11(12):1683-92.

45: Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. *Neurology*. 2011 Nov 22;77(21):1887-95.

46: Ruggieri M, Serpino C, Ceci E, Scirucchio V, Franco G, Pica C, Trojano M, Livrea P, de Tommaso M. Serum levels of N-acetylaspartate in Huntington's disease: preliminary results. *Mov Disord*. 2012 Feb;27(2):329-30.

47: Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β -1a in the COGNitive Impairment in MULTiple Sclerosis (COGIMUS) study. *BMC Neurol*. 2011 Oct 14;11:125.

48: O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med*. 2011 Oct 6;365(14):1293-303.

49: Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Grimaldi LM; COGIMUS study group. Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β -1a: results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study (II). *Qual Life Res*. 2012 Sep;21(7):1111-21.

50: Goretti B, Portaccio E, Ghezzi A, Lori S, Moiola L, Falautano M, Viterbo R, Patti F, Vecchio R, Pozzilli C, Bianchi V, Cappiello S, Comi G, Trojano M, Amato MP; Multiple Sclerosis Study Group of the Italian Neurological Society. Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. *Mult Scler*. 2012 Mar;18(3):329-34.

51: Portaccio E, Ghezzi A, Hakiki B, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, De Luca G, Paolicelli D, Marrosu MG, Comi G, Trojano M, Amato MP; MS Study Group of the Italian Neurological Society. Breastfeeding is not related to postpartum relapses in multiple sclerosis. *Neurology*. 2011 Jul 12;77(2):145-50.

52: Girolamo F, Ferrara G, Strippoli M, Rizzi M, Errede M, Trojano M, Perris R, Roncali L, Svelto M, Mennini T, Virgintino D. Cerebral cortex demyelination and oligodendrocyte precursor response to experimental autoimmune encephalomyelitis. *Neurobiol Dis*. 2011 Sep;43(3):678-89.

53: Martino D, Chiarotti F, Buttiglione M, Cardona F, Creti R, Nardocci N, Orefici G, Veneselli E, Rizzo R; Italian Tourette Syndrome Study Group. The relationship between group A streptococcal infections and Tourette syndrome: a study on a large service-based cohort. *Dev Med Child Neurol*. 2011 Oct;53(10):951-7.

54: Tortorella C, Ruggieri M, Di Monte E, Ceci E, Iaffaldano P, Drenzo V, Mastrapasqua M, Frigeri A, Amato MP, Hakiki B, Ghezzi A, Lugaresi A, De Luca G, Patti F, D'Amico E, Sola P, Simone AM, Svelto M, Livrea P, Trojano M. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. *J Neurol Neurosurg Psychiatry*. 2011 Dec;82(12):1355-9.

55: Giordano A, Granella F, Lugaresi A, Martinelli V, Trojano M, Confalonieri P, Radice D, Solari A; SIMS-Trial group. Anxiety and depression in multiple sclerosis patients around diagnosis. *J Neurol Sci*. 2011 Aug 15;307(1-2):86-91.

56: Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurol*. 2011 Jun;10(6):520-9.

57: Trojano M. Multiple sclerosis: the evolving diagnostic criteria for multiple

sclerosis. *Nat Rev Neurol*. 2011 May;7(5):251-2.

58: Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C; COGIMUS Study Group. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study. *Mult Scler*. 2011 Aug;17(8):991-1001.

59: Trojano M, Paolicelli D, Tortorella C, Iaffaldano P, Lucchese G, Di Renzo V, D'Onghia M. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? *Neurol Clin*. 2011 May;29(2):309-21.

60: Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M; French-Italian Mitoxantrone Interferon-beta-1b Trial Group. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. *J Neurol Neurosurg Psychiatry*. 2011 Dec;82(12):1344-50.

61: Ruggieri M, Tortorella C, Ceci E, Paolicelli D, Solfrizzi V, Di Bitonto G, Pica C, Mastrapasqua M, Livrea P, Trojano M. Age-related changes of serum N-acetyl-aspartate in healthy controls. *Age Ageing*. 2011 May;40(3):391-5.

62: Patti F, Amato MP, Trojano M, Solaro C, Pappalardo A, Zipoli V, Portaccio E, Paolicelli D, Paolillo A, Mennini FS, Marcellusi A, Ricci C, Battaglia MA. Multiple sclerosis in Italy: cost-of-illness study. *Neurol Sci*. 2011 Oct;32(5):787-94.

63: Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Trojano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi A, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone S, Savettieri G, Tedeschi G; MS-SIN Study Group. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. *Neurol Sci*. 2011 Apr;32(2):351-8.

64: Pisani F, Mastrototaro M, Rossi A, Nicchia GP, Tortorella C, Ruggieri M, Trojano M, Frigeri A, Svelto M. Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. *J Biol Chem*. 2011 Mar 18;286(11):9216-24.

65: Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L,

Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M; MS Study Group of the Italian Neurological Society. Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. *Neurology*. 2010 Nov 16;75(20):1794-802.

66: Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Moidola L, Falautano M, De Caro MF, Viterbo R, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Martinelli V, Comi G, Portaccio E, Trojano M; Multiple Sclerosis Study Group of the Italian Neurological Society. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. *Neurology*. 2010 Sep 28;75(13):1134-40.

67: Solari A, Martinelli V, Trojano M, Lugaresi A, Granella F, Giordano A, Messmer Uccelli M, D'Alessandro R, Pucci E, Confalonieri P, Borreani C; SIMS-Trial group. An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. *Mult Scler*. 2010 Nov;16(11):1393-405.

68: Solari A, Mattarozzi K, Vignatelli L, Giordano A, Russo PM, Uccelli MM, D'Alessandro R; SIMS-Trial group; GERONIMUS group. Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. *Mult Scler*. 2010 Oct;16(10):1237-47.

69: Trojano M. Improving combination trials for multiple sclerosis. *Lancet Neurol*. 2010 Jul;9(7):646-7.

70: Goretti B, Ghezzi A, Portaccio E, Lori S, Zipoli V, Razzolini L, Moidola L, Falautano M, De Caro MF, Viterbo R, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Comi G, Trojano M, Amato MP; Study Group of the Italian Neurological Society. Psychosocial issue in children and adolescents with multiple sclerosis. *Neurol Sci*. 2010 Aug;31(4):467-70.

71: Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. *J Neurol Sci*. 2010 May 15;292(1-2):28-35.

72: Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. *N Engl J Med*. 2010 Feb 4;362(5):416-26.

73: Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):402-15.

74: Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. *Mult Scler.* 2010 Jan;16(1):68-77.

75: Giordano A, Uccelli MM, Pucci E, Martinelli V, Borreani C, Lugaresi A, Trojano M, Granella F, Confalonieri P, Radice D, Solari A; SIMS-Trial group. The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. *Mult Scler.* 2010 Jan;16(1):100-11.

76: Iaffaldano P, D'Onghia M, Trojano M. Safety profile of Tysabri: international risk management plan. *Neurol Sci.* 2009 Oct;30 Suppl 2:S159-62.

77: Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V. observational studies: propensity score analysis of non-randomized data. *Int MS J.* 2009 Sep;16(3):90-7.

78: Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espiño M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuč E, Paraskevas GP, Pirttilä T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vécsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen CE. Neurofilament ELISA validation. *J Immunol Methods.* 2010 Jan 31;352(1-2):23-31.

79: Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Zipoli V, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network (MSDN) Group. Real-life impact of early interferon beta therapy in

relapsing multiple sclerosis. *Ann Neurol.* 2009 Oct;66(4):513-20.

80: Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C, Confavreux C; Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis Study Group. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. *J Neurol Sci.* 2009 Nov 15;286(1-2):114-8.

81: O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *Lancet Neurol.* 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Erratum in: *Lancet Neurol.* 2011 Feb;10(2):115. *Lancet Neurol.* 2009 Nov;8(11):981. *Lancet Neurol.* 2012 Jan;11(1):27.

82: Paolicelli D, Drenzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. *Biologics.* 2009;3:369-76.

83: Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, Tortorella C, Simone IL, Patti F, Ghezzi A, Portaccio E, Rossi P, Pozzilli C, Salemi G, Lugaresi A, Bergamaschi R, Millefiorini E, Clerico M, Lus G, Vianello M, Avolio C, Cavalla P, Iaffaldano P, Drenzo V, D'Onghia M, Lepore V, Livrea P, Comi G, Amato MP; Italian Multiple Sclerosis Database Network Group. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. *J Neurol Sci.* 2009 Nov 15;286(1-2):109-13.

84: Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. *Mult Scler.* 2009 Jul;15(7):779-88.

85: Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. *Neurol Sci.* 2009 Jun;30(3):193-9.

86: Trojano M, Avolio C. Epstein-Barr virus (EBV) and multiple sclerosis

association: EBV has a primary or secondary role? *J Neurol Neurosurg Psychiatry*. 2009 May;80(5):469.

87: Hussain H, Usman A, Raza Q, Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, Moiola L, Falautano M, De Caro MF, Lopez M, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Comi G, Trojano M. Cognitive and psychosocial features of childhood and juvenile MS. *Neurology*. 2009 Mar 31;72(13):1189; author reply1189-90.

88: Portaccio E, Goretti B, Lori S, Zipoli V, Centorrino S, Ghezzi A, Patti F, Bianchi V, Comi G, Trojano M, Amato MP; Multiple Sclerosis Study Group of the Italian Neurological Society. The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. *Mult Scler*. 2009 May;15(5):620-6.

89: Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Lijoi F, Goretti B, Messina S, Picconi O, Tola MR, Trojano M. Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. *Ther Adv Neurol Disord*. 2009 Mar;2(2):67-77.

90: Nicchia GP, Mastrototaro M, Rossi A, Pisani F, Tortorella C, Ruggieri M, Lia A, Trojano M, Frigeri A, Svelto M. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. *Glia*. 2009 Oct;57(13):1363-73.

91: Bellomi F, Bramanti P, Trojano M, Scagnolari C, Muto A, Sessa E, La Volpe V, Russo P, Antonelli G. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres. *J Immunoassay Immunochem*. 2009;30(1):40-50.

92: Trojano M, Paolicelli D, Fuiani A, Pellegrini F, Iaffaldano P, Drenzo V, D'Onghia M. Postmarketing evidence of disease-modifying drugs in multiple sclerosis. *Neurol Sci*. 2008 Sep;29 Suppl 2:S225-6.

93: Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. *Lancet Neurol*. 2008 Oct;7(10):903-14.

94: Cocco E, Sardu C, Gallo P, Capra R, Amato MP, Trojano M, Uccelli A, Marrosu MG; FEMIMS Group. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. *Mult Scler*. 2008 Nov;14(9):1225-33.

95: Italian REMS Study Group, Manconi M, Ferini-Strambi L, Filippi M, Bonanni E, Iudice A, Murri L, Gigli GL, Fratticci L, Merlino G, Terzano G, Granella F, Parrino L, Silvestri R, Aricò I, Dattola V, Russo G, Luongo C, Cicolin A, Tribolo A, Cavalla P, Savarese M, Trojano M, Ottaviano S, Cirignotta F, Simioni V, Salvi F, Mondino F, Perla F, Chinaglia G, Zuliani C, Cesnik E, Granieri E, Placidi F, Palmieri MG, Manni R, Terzaghi M, Bergamaschi R, Rocchi R, Ulivelli M, Bartalini S, Ferri R, Lo Fermo S, Ubiali E, Viscardi M, Rottoli M, Nobili L, Protti A, Ferrillo F, Allena M, Mancardi G, Guarnieri B, Londrillo F. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. *Sleep*. 2008 Jul;31(7):944-52.

96: Ruggieri M, Pica C, Lia A, Zimatore GB, Modesto M, Di Liddo E, Specchio LM, Livrea P, Trojano M, Avolio C. Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. *J Neuroimmunol*. 2008 Jul 15;197(2):140-6.

97: Ramunni A, De Robertis F, Brescia P, Saliani MT, Amoruso M, Prontera M, Dimonte E, Trojano M, Coratelli P. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis. *Ther Apher Dial*. 2008 Jun;12(3):250-4.

98: Cappellano G, Orilieri E, Comi C, Chiocchetti A, Bocca S, Boggio E, Bernardone IS, Cometa A, Clementi R, Barizzone N, D'Alfonso S, Corrado L, Galimberti D, Scarpini E, Guerini FR, Caputo D, Paolicelli D, Trojano M, Figà-Talamanca L, Salvetti M, Perla F, Leone M, Monaco F, Dianzani U. Variations of the perforin gene in patients with multiple sclerosis. *Genes Immun*. 2008 Jul;9(5):438-44.

99: Amato MP, Goretti B, Ghezzi A, Lori S, Zipoli V, Portaccio E, Muiola L, Falautano M, De Caro MF, Lopez M, Patti F, Vecchio R, Pozzilli C, Bianchi V, Roscio M, Comi G, Trojano M; Multiple Sclerosis Study Group of the Italian Neurological Society. Cognitive and psychosocial features of childhood and juvenile MS. *Neurology*. 2008 May 13;70(20):1891-7.

100: D'Alfonso S, Bolognesi E, Guerini FR, Barizzone N, Bocca S, Ferrante D, Castelli L, Bergamaschi L, Agliardi C, Ferrante P, Naldi P, Leone M, Caputo D, Ballerini C, Salvetti M, Galimberti D, Massacesi L, Trojano M, Momigliano-Richiardi P. A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. *Genes Immun*. 2008 Jan;9(1):7-15.

101: Trojano M. Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis? *Neurology*. 2007 Oct 9;69(15):1478-9.

102: Ruggieri M, Avolio C, Livrea P, Trojano M. Glatiramer acetate in multiple sclerosis: a review. *CNS Drug Rev.* 2007 Summer;13(2):178-91. Review.

103: Solari A, Acquarone N, Pucci E, Martinelli V, Marrosu MG, Trojano M, Borreani C, Messmer Uccelli M. Communicating the diagnosis of multiple sclerosis - a qualitative study. *Mult Scler.* 2007 Jul;13(6):763-9.

104: Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, Milanese C, Moiola L, Milani N, La Mantia L, Patti F, Pozzilli C, Trojano M, Comi G, Zaffaroni M; Immunomodulatory Treatment of Early-onset MS (ITEMS) Group. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. *Neurol Sci.* 2007 Jun;28(3):127-32.

105: Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP. New natural history of interferon-beta-treated relapsing multiple sclerosis. *Ann Neurol.* 2007 Apr;61(4):300-6.

106: Patti F, Amato MP, Battaglia MA, Pitaro M, Russo P, Solaro C, Trojano M. Caregiver quality of life in multiple sclerosis: a multicentre Italian study. *Mult Scler.* 2007 Apr;13(3):412-9.

107: Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavalpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. *J Neurol.* 2007 May;254(5):597-604.

108: Giorelli M, Livrea P, Minervini MG, Trojano M. Immunomodulatory properties of increased levels of liver X receptor beta in peripheral blood mononuclear cells from multiple sclerosis patients. *Exp Neurol.* 2007 Apr;204(2):759-66.

109: Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF, Patti F, Vecchio R, Sorbi S, Trojano M. The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. *Mult Scler.* 2006 Dec;12(6):787-93.

110: Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski JP. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. *Mult Scler.* 2006 Dec;12(6):769-74.

111: Bergamaschi R, Quaglini S, Trojano M, Amato MP, Tavazzi E, Paolicelli D,

Zipoli V, Romani A, Fuiani A, Portaccio E, Berzuini C, Montomoli C, Bastianello S, Cosi V. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. *J Neurol Neurosurg Psychiatry*. 2007 Jul;78(7):757-9.

112: Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, Granieri E, Rosati G, Savettieri G, Comi G, Livrea P; MSDN Study Group. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. *Mult Scler*. 2006 Oct;12(5):578-85.

113: Trojano M, Paolicelli D, Lepore V, Fuiani A, Di Monte E, Pellegrini F, Russo P, Livrea P, Comi G; Italian MSDN Group. Italian Multiple Sclerosis Database Network. *Neurol Sci*. 2006 Sep;27 Suppl 5:S358-61.

114: Games Collaborative Group, Ban M, Booth D, Heard R, Stewart G, Goris A, Vandebroek K, Dubois B, Laaksonen M, Ilonen J, Alizadeh M, Edan G, Babron MC, Brassat D, Clanet M, Cournu-Rebeix I, Fontaine B, Semana G, Goedde R, Epplen J, Weber A, Infante-Duarte C, Zipp F, Rajda C, Bencsik K, Vécsei L, Heggarty S, Graham C, Hawkins S, Liguori M, Momigliano-Richiardi P, Caputo D, Grimaldi LM, Leone M, Massacesi L, Milanese C, Salvetti M, Savettieri G, Trojano M, Bielecki B, Mycko MP, Selmaj K, Santos M, Maciel P, Pereira C, Silva A, Silva BM, Coraddu F, Marrosu MG, Akesson E, Hillert J, Datta P, Oturai A, Harbo HF, Spurkland A, Goertsches R, Villoslada P, Eraksoy M, Hensiek A, Compston A, Setakis E, Gray J, Yeo TW, Sawcer S. Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. *J Neuroimmunol*. 2006 Oct;179(1-2):108-16.

115: Amato MP, Zipoli V, Goretti B, Portaccio E, De Caro MF, Ricchiuti L, Siracusa G, Masini M, Sorbi S, Trojano M. Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. *J Neurol*. 2006 Aug;253(8):1054-9.

116: Nocentini U, Pasqualetti P, Bonavita S, Buccafusca M, De Caro MF, Farina D, Girlanda P, Le Pira F, Lugaresi A, Quattrone A, Reggio A, Salemi G, Savettieri G, Tedeschi G, Trojano M, Valentino P, Caltagirone C. Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. *Mult Scler*. 2006 Feb;12(1):77-87.

117: Trojano M, Paolicelli D, Zimatore GB, De Robertis F, Fuiani A, Di Monte E, Livrea P. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. *Neurol Sci*. 2005 Dec;26 Suppl 4:S179-82.

118: Tortorella C, Bellacosa A, Paolicelli D, Fuiani A, Di Monte E, Simone IL, Giaquinto P, Livrea P, Trojano M. Age-related gadolinium-enhancement of MRI brain

lesions in multiple sclerosis. *J Neurol Sci.* 2005 Dec 15;239(1):95-9.

119: Ruggieri M, Avolio C, Scacco S, Pica C, Lia A, Zimatore GB, Papa S, Livrea P, Trojano M. Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients. *J Neurol.* 2006 Feb;253(2):231-6.

120: Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F, Tomassini V, Pozzilli C, Stecchi S, Giaquinto P, Livrea P, Trojano M. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. *Mult Scler.* 2005 Aug;11(4):441-6.

121: Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, Milani N, Milanese C, Moiola L, Patti F, Pilato V, Pozzilli C, Trojano M, Zaffaroni M, Comi G; Immunomodulatory Treatment of Early onset MS Group. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. *Mult Scler.* 2005 Aug;11(4):420-4.

122: Giorelli M, Livrea P, Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. *J Interferon Cytokine Res.* 2005 Jul;25(7):395-406.

123: Chiocchetti A, Comi C, Indelicato M, Castelli L, Mesturini R, Bensi T, Mazzarino MC, Giordano M, D'Alfonso S, Momigliano-Richiardi P, Liguori M, Zorzon M, Amoroso A, Trojano M, Monaco F, Leone M, Magnani C, Dianzani U. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. *J Neuroimmunol.* 2005 Jun;163(1-2):172-8.

124: Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Milterski B, Eppelen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. *Neurology.* 2005 Apr 12;64(7):1144-51.

125: Sisto D, Trojano M, Vetrugno M, Trabucco T, Iliceto G, Sborgia C. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. *Invest Ophthalmol Vis Sci.* 2005 Apr;46(4):1264-8.

126: Ghezzi A, Ruggieri M, Trojano M, Filippi M; ITEMS Study Group. Italian studies on early-onset multiple sclerosis: the present and the future. *Neurol Sci.* 2004 Nov;25 Suppl 4:S346-9.

127: Trojano M, Paolicelli D, Bellacosa A, Fuiani A, Cataldi S, Di Monte E. Atypical forms of multiple sclerosis or different phases of a same disease? *Neurol Sci.* 2004 Nov;25 Suppl 4:S323-5.

128: Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C; Evaluation of the EDMUS system (EVALUED) Study Group. European validation of a standardized clinical description of multiple sclerosis. *J Neurol.* 2004 Dec;251(12):1472-80.

129: Trojano M. Can databasing optimise patient care? *J Neurol.* 2004 Sep;251 Suppl 5:v79-v82.

130: Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, Farina D, Fazio MC, Girlanda P, Le Pira F, Liguori M, Lugaresi A, Nocentini U, Reggio A, Salemi G, Tedeschi G, Trojano M, Valentino P, Quattrone A. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. *J Neurol.* 2004 Oct;251(10):1208-14.

131: Solaro C, Bricchetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, Gasperini C, Ghezzi A, Martinelli V, Milanese C, Patti F, Trojano M, Verdun E, Mancardi GL; PalMS Study Group. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. *Neurology.* 2004 Sep 14;63(5):919-21.

132: Giorelli M, Livrea P, Trojano M. Post-receptorial mechanisms underlie functional dysregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. *J Neuroimmunol.* 2004 Oct;155(1-2):143-9.

133: Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. *J Neurol Sci.* 2004 Aug 15;223(1):69-71.

134: Cosentino M, Zaffaroni M, Giorelli M, Marino F, Ferrari M, Bombelli R, Rasini E, Trojano M, Lecchini S, Livrea P, Comi G, Frigo G. Adrenergic mechanisms in multiple sclerosis: the neuro-immune connection? *Trends Pharmacol Sci.* 2004 Jul;25(7):350-1; author reply 351-2.

135: Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G; Italian Devic's Study Group (IDESG). Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. *J Neurol.* 2004 Jan;251(1):47-52.

136: Liguori M, Cittadella R, Manna I, Valentino P, La Russa A, Serra P, Trojano M, Messina D, Ruscica F, Andreoli V, Romeo N, Livrea P, Quattrone A. Association

between Synapsin III gene promoter polymorphisms and multiple sclerosis. J
Neurol. 2004 Feb;251(2):165-70.